Novo
Jul 18, 2017
Takeda scores; PhRMA launches; Valeant’s Obagi; Ex-Novo executive signs
Takeda scores blockbuster Velcade patent reprieve till 2022 In a major lift for Takeda and its aging multiple myeloma blockbuster Velcade, a U.S. appeals court overturned a ruling that invalidated a key patent, granting new exclusivity that should translate to significant sales over time. Takeda will have exclusive ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
